Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Real-world evidence has a place in cancer immunotherapy
However, some challenges still limit its implementation in clinical practice
Targeting claudins in pancreatic adenocarcinoma is promising, early-phase findings suggest
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Immunotherapy combinations consolidate their place in the first-line treatment of unresectable hepatocellular carcinoma
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials
Short durvalumab infusions appear to be safe for the first-line treatment of advanced biliary tract cancer
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients
Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials
Promising results support the further development of new small-molecule PD-L1 inhibitors with favourable benefit–risk profiles and improved ease of use compared with antibodies
Studies present a wider application of sequencing techniques for the treatment of cancer
Whole-genome sequencing and single-cell sequencing can provide valuable insights not only in the identification of new therapy targets, but also to assess minimal residual disease and overcome treatment resistance